Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Perou
Univ of North Carolina Chapel Hill, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bioclassifier and GeneCentric Diagnostics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The SFIs of the investigator are related to the funded research since the technology being used in the project has been licensed to the company with which the investigator has multiple relationships.
The Institution has determined that since the technology could be further validated as a result of the research, these financial interests could conflict with project.
SPORE in Breast Cancer
The UNC Breast Cancer SPORE contributes to the clinical application of molecular subtyping to breast cancer discovery, prognostication, conduct of clinical trials, and understanding of minority disparities in breast cancer. Our projects continue to explore the effect of intrinsic subtype on the predisposition, progression, and therapeutic resistance of difficult-to-treat breast cancers. UNO SPORE's technology development, population-based studies, and analysis of clinical trials will have substantial translational impact.
Filed on December 20, 2017.
Tell us what you know about Charles Perou's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Charles Perou filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles Perou | Univ of North Carolina Chapel Hill | Conflict of Interest | Bioclassifiers, Llc | $80,000 - $99,999 |
| Charles Perou | Univ of North Carolina Chapel Hill | Conflict of Interest | GeneCentric Therapeutics, Inc. | $60,000 - $79,999 |
| Charles Perou | Univ of North Carolina Chapel Hill | Conflict of Interest | GeneCentric Therapeutics, Inc. | $0 - $4,999 |
| Charles Perou | Univ of North Carolina Chapel Hill | Conflict of Interest | Bioclassifiers, Llc | $0 - $4,999 |
| Charles Perou | Univ of North Carolina Chapel Hill | Conflict of Interest | Bioclassifier and GeneCentric Diagnostics | $0 - $4,999 |
| Charles Perou | Univ of North Carolina Chapel Hill | Conflict of Interest | Bioclassifiers, Llc | Value cannot be readily determined |
| Charles Perou | Univ of North Carolina Chapel Hill | Conflict of Interest | Bioclassifier and GeneCentric Diagnostics | Value cannot be readily determined |
| Charles Perou | Univ of North Carolina Chapel Hill | Conflict of Interest | GeneCentric Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.